Search Results - "Facon T"

Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' reply.

Authors: Manier S Lambert J Hulin C et al.

Source: The Lancet. Oncology [Lancet Oncol] 2026 Feb; Vol. 27 (2), pp. e65.

Publication Type: Letter

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE; In Process

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Authors: Usmani SZ Facon T Hungria V et al.

Source: Nature medicine [Nat Med] 2025 Apr; Vol. 31 (4), pp. 1366.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE

Toward a cure for multiple myeloma within a decade.

Authors: Mohty M Malard F Facon T et al.

Source: Blood cancer journal [Blood Cancer J] 2026 Mar 10; Vol. 16 (1). Date of Electronic Publication: 2026 Mar 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Vaccination and Antiviral Combination Improves Resolution Time of COVID‐19 Infection in Treated Multiple Myeloma: A Retrospective Study.

Authors: Di Cecca, M. V., Bongarzoni M., Garzia et al.

Source: Advances in Hematology. 6/15/2026, Vol. 2026, p1-7. 7p.

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Authors: Moreau P Hulin C Talbot A et al.

Source: Blood cancer journal [Blood Cancer J] 2025 Oct 24; Vol. 15 (1), pp. 177. Date of Electronic Publication: 2025 Oct 24.

Publication Type: Journal Article; Review

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Optimal control of multiple myeloma assuming drug resistance and off-target effects.

Authors: Lefevre, James G. Lawson, Brodie A. J. Burrage, Pamela M. et al.

Source: PLoS Computational Biology. 8/11/2025, Vol. 21 Issue 8, p1-21. 21p.

Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.

Authors: Chalayer E Frere C Daguenet E et al.

Source: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2025 Oct; Vol. 23 (10), pp. 3220-3230. Date of Electronic Publication: 2025 Jun 14.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101170508 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7836 (Electronic) Linking ISSN: 15387836 NLM ISO Abbreviation: J Thromb Haemost Subsets: MEDLINE

Prognostic stratification of standard risk multiple myeloma defined by revised international scoring system.

Authors: Barilà, Gregorio Bonaldi, Laura Martines, Annalisa et al.

Source: Leukemia & Lymphoma. Sep2025, Vol. 66 Issue 9, p1740-1744. 5p.

Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma.

Authors: Zhou, Hongmei Zhang, Min Jin, Yi et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-12. 12p.

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Authors: Boccadoro, Mario Belotti, Angelo Bombaci, Felice et al.

Source: BMC Cancer. 10/31/2025, Vol. 25 Issue 1, p1-12. 12p.

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.

Authors: Bergiers, Isabelle Köse, Murat Cem Skerget, Sheri et al.

Source: PLoS Genetics. 10/7/2025, Vol. 21 Issue 10, p1-29. 29p.

The challenge of non-transplant eligible, newly diagnosed multiple myeloma.

Authors: Ntanasis-Stathopoulos, Ioannis Solia, Eirini Filippatos, Charalampos et al.

Source: Leukemia & Lymphoma. Oct2025, Vol. 66 Issue 10, p1767-1777. 11p.

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG).

Authors: Kastritis, Efstathios Katodritou, Eirini Badelita, Sorina et al.

Source: Leukemia & Lymphoma. Dec2024, Vol. 65 Issue 13, p2064-2067. 4p.

Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report.

Authors: Mettias, Sarah Cheung, Jamie Moore, Jonathan et al.

Source: Case Reports in Oncology. Feb2026, Vol. 19 Issue 1, p410-416. 7p. 1 Illustration.

Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744).

Authors: Tan, Melinda S. Y. Nagarajan, Chandramouli Ooi, Melissa et al.

Source: Leukemia & Lymphoma. Feb2026, Vol. 67 Issue 3, p600-607. 8p.

Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study.

Authors: Lee, Ji Yun Kim, Sang-A Koh, Youngil et al.

Source: Cancer Research & Treatment. Jan2026, Vol. 58 Issue 1, p311-319. 9p.

Application of the New IMWG/IMS High-Risk Classification for Multiple Myeloma: Analysis of a Large Real-World Romanian Cohort.

Authors: Badelita, Sorina Nicoleta Barbu, Sinziana Calugaru, Onda-Tabita et al.

Source: International Journal of Molecular Sciences. May2026, Vol. 27 Issue 10, p4620. 17p.

Complex Chromothripsis-like Features in Plasma Cell Myeloma: A Case Report and Review of the Literature.

Authors: Oentoro, Jaymie Yu, Sonia Murgas, Kevin A. et al.

Source: Diagnostics (2075-4418). May2026, Vol. 16 Issue 9, p1280. 10p.

Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.

Authors: Rahman, Raeef Zayad, Anas Awadallah, Carmel et al.

Source: Current Oncology. May2026, Vol. 33 Issue 5, p246. 17p.

Extramedullary manifestation of multiple myeloma presenting as infraorbital swelling: a rare case report.

Authors: Kavarthapu, Srilatha Jakka, Sree Devi Singh, Deepali et al.

Source: Journal of Rare Diseases. 4/7/2026, Vol. 5 Issue 1, p1-7. 7p.